A. Fujioka

发表

Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.

S. Tsukagoshi, Y. Saga, N. Suzuki, 2003, International journal of oncology.

Contrasting effects of extended low dose versus standard dose shorter course UFT chemotherapy on microscopic versus macroscopic established tumors: implications for optimal postoperative adjuvant chemotherapy.

A. Fujioka, M. Fukushima, Y. Sugimoto, 2007, Oncology reports.

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

A. Fujioka, F. Nakagawa, H. Okabe, 2014, Oncology reports.

An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.

A. Fujioka, F. Nakagawa, H. Okabe, 2004, International journal of molecular medicine.

Abstract 1783: Trifluorothymidine incorporation into DNA strongly enforces the potential of TAS-102 and leads to remarkably prolonged survival of cancer patients

A. Fujioka, H. Okabe, Takamasa Suzuki, 2012 .

Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5-fluorouracil] with uracil, by oral l-leucovorin.

A. Fujioka, H. Okabe, K. Nakano, 1997, Anticancer research.

Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.

A. Fujioka, M. Fukushima, J. Uchida, 1996, Cancer research.

Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.

A. Fujioka, M. Fukushima, E. Matsushima, 2002, European journal of cancer.

Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo.

A. Fujioka, F. Nakagawa, M. Fukushima, 2001, European journal of cancer.

pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line

A. Fujioka, M. Fukushima, A. Matsuda, 2005 .

Possible antitumor activity of 1‐(3‐C‐ethynyl‐β‐d‐ribo‐pentofuranosyl)cytosine (ECyd, TAS‐106) against an established gemcitabine (dFdCyd)‐resistant human pancreatic cancer cell line

A. Fujioka, M. Fukushima, A. Matsuda, 2005, Cancer science.

Prolongation of survival period and improvement of cancer cachexia by long-term administration of UFT.

A. Fujioka, J. Uchida, K. Nakano, 1996, Cancer letters.

Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice.

A. Fujioka, M. Kurosumi, R. Dickson, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

A. Fujioka, Kimihiro Ito, R. Wadhwa, 2019, Molecular Cancer Therapeutics.

Relationship between Protein Levels and Gene Expression of Dihydropyrimidine Dehydrogenase in Human Tumor Cells during Growth in Culture and in Nude Mice

A. Fujioka, M. Fukushima, Y. Murakami, 1998, Japanese journal of cancer research : Gann.

Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.

N. Suzuki, A. Fujioka, M. Fukushima, 2005, International journal of oncology.

Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.

N. Suzuki, A. Fujioka, M. Fukushima, 2005, International journal of oncology.

1,2,3-Triazole-containing uracil derivatives with excellent pharmacokinetics as a novel class of potent human deoxyuridine triphosphatase inhibitors.

A. Fujioka, S. Shuto, T. Wakasa, 2012, Journal of medicinal chemistry.

Discovery of highly potent human deoxyuridine triphosphatase inhibitors based on the conformation restriction strategy.

A. Fujioka, S. Shuto, T. Wakasa, 2012, Journal of medicinal chemistry.

Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells.

A. Fujioka, M. Fukushima, J. Uchida, 1997, International journal of oncology.

TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy

A. Fujioka, T. Wakasa, K. T. Chong, 2018, Molecular Cancer Therapeutics.

1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo.

A. Fujioka, M. Fukushima, Y. Wataya, 2009, International Journal of Oncology.

Antitumor Activity and Pharmacokinetics of TAS‐106, l‐(3‐C‐Ethynyl‐β‐D‐ribo‐pentofuranosyl)cytosine

A. Fujioka, M. Fukushima, A. Matsuda, 2001, Japanese journal of cancer research : Gann.

(ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo

A. Fujioka, M. Fukushima, Y. Wataya, 2009 .

dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells

A. Fujioka, T. Wakasa, S. Ohkubo, 2020, Cancer science.

Discovery of a novel class of potent human deoxyuridine triphosphatase inhibitors remarkably enhancing the antitumor activity of thymidylate synthase inhibitors.

A. Fujioka, S. Shuto, T. Wakasa, 2012, Journal of medicinal chemistry.

Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.

A. Fujioka, M. Fukushima, J. Uchida, 1998, International journal of oncology.

Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59)

A. Fujioka, H. Saito, K. Wierzba, 2000, Cancer Chemotherapy and Pharmacology.

Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer

A. Fujioka, Gotaro Tanaka, H. Nagase, 2023, Chemotherapy.

Experimental postoperative adjuvant chemotherapy by UFT using primary tumor amputation model.

A. Fujioka, J. Uchida, H. Okabe, 2000, International journal of molecular medicine.

Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.

A. Fujioka, M. Fukushima, H. Okabe, 2005, Oncology reports.